Twist Bioscience Corp. Hits New 52-Week High of $69.19

Twist Bioscience Corp. has reached a significant milestone by hitting a new 52-week high of USD 69.19 on May 28, 2026. This achievement highlights the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 2.76 billion. Over the past year, Twist Bioscience has demonstrated a robust performance, with a 38.03% increase, outperforming the S&P 500, which recorded a 28.45% gain during the same period. Despite being a loss-making company, Twist Bioscience's financial metrics reflect its position in the market. The company has a price-to-book ratio of 6.05, indicating its valuation relative to its assets. Additionally, the debt-to-equity ratio stands at -0.41, suggesting a unique financial structure. However, the return on equity is currently at -16.79%, reflecting challenges in generating profit from its equity base. The absence of a dividend yield further emphasizes the company's focus on growth and reinvestment in its operations.